Application of MSC mesenchymal stem cell gene therapy CGT

Research Solution for MSC Mesenchymal Stem Cells（Application of MSC mesenchymal stem cell gene therapy CGT）

Mesenchymal stem cells (MSCs) are a type of adult stem cell with multipotent differentiation potential, isolated from bone marrow by Friedenstein in 1968. MSCs exist in various tissues, with common sources including bone marrow, adipose tissue, umbilical cord and placenta, dental pulp, and synovium. MSCs can not only self renew, but also differentiate into various cell types, including osteoblasts, chondrocytes, adipocytes, muscle cells, and nerve cells. Due to its differentiation ability, immune regulatory properties, and low immunogenicity, MSCs have broad application prospects in regenerative medicine, anti-inflammatory, anti fibrotic, and other fields.

For more content, please visit the Manbo Biotechnology website:Application of MSC mesenchymal stem cell gene therapy CGTplan

MSC therapy and its main application areas:

As of November 2024, more than 1300 clinical trials of mesenchymal stem cells have been retrieved from ClinicalTrials.gov website, showing the therapeutic potential of * in the fields of osteoarthritis, stroke, Parkinson's disease, diabetes, heart failure and other diseases. Most studies use MSCs derived from fat or bone marrow. Nearly 75% of clinical studies use MSCs as regenerative medicine products, approximately 14% use MSCs for disease modeling, and the remaining 11% use MSCs for drug discovery and cytotoxicity testing applications.

As of June 2024, 95 stem cell drugs from 52 domestic stem cell pharmaceutical companies have entered CDE and obtained implied clinical trial licenses. On January 2, 2025, the first stem cell therapy drug in China, Amimatosa Injection, was conditionally approved for market through the priority review and approval process. Its indication is for the treatment of acute graft-versus-host disease (aGVHD) mainly involving gastrointestinal tract involvement in patients over 14 years old who have failed hormone therapy. The acceleration of research and development has enhanced the expectations of the stem cell market prospects, and also indicates that stem cell therapy will become an important development direction in the medical and health field in the future.

·Regenerative medicine: including fields such as bone repair, cartilage regeneration, muscle repair, nerve repair, and cardiac repair;

·Immune regulation and anti-inflammatory: covering rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, and graft-versus-host disease (GVHD), etc;

·Anti fibrotic therapy: mainly used for liver fibrosis, pulmonary fibrosis, renal fibrosis, etc;

·Treatment of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and spinal cord injury;

·Cardiovascular disease treatment: involving myocardial infarction, heart failure, and peripheral vascular disease;

·Treatment of diabetes: including diabetes foot ulcer, type 1 diabetes and type 2 diabetes;

·Drug delivery: used for targeted therapy and drug delivery;

·Beauty and skin repair: covering anti-aging and skin wound repair;

·Hair regeneration: mainly used for hair loss treatment and hair follicle repair.

From R&D to process development to clinical production GMP level solutions: